Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$90.6m

Nuvectis Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:NVCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Dec 24BuyUS$228,941Charles Mosseri-MarlioIndividual49,121US$4.70
19 Nov 24BuyUS$9,980Enrique PoradosuIndividual2,000US$4.99
15 Nov 24BuyUS$98,400Ron BentsurIndividual20,000US$4.92
07 Nov 24SellUS$22,478Michael CarsonIndividual2,755US$8.16
14 May 24BuyUS$13,076Ron BentsurIndividual1,940US$6.74
10 May 24BuyUS$7,034Shay ShemeshIndividual1,113US$6.32
10 May 24BuyUS$3,145Enrique PoradosuIndividual500US$6.29
10 May 24BuyUS$12,800Ron BentsurIndividual2,000US$6.40
18 Mar 24BuyUS$51,450Ron BentsurIndividual5,000US$10.29

Insider Trading Volume

Insider Buying: NVCT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NVCT?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,361,8107.05%
General Public5,801,26830%
Individual Insiders12,157,89562.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.

Top Shareholders

Top 25 shareholders own 69.52% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16%
Ron Bentsur
3,086,424US$14.5m0.65%no data
13.7%
Charles Mosseri-Marlio
2,644,121US$12.4m1.89%no data
12.3%
Charles Marlio
2,380,176US$11.2m0%no data
7.3%
Enrique Poradosu
1,409,652US$6.6m0.14%no data
7.23%
Shay Shemesh
1,396,401US$6.5m0%no data
4.7%
Thomas Peters
908,475US$4.3m0%no data
1.56%
The Vanguard Group, Inc.
301,138US$1.4m19.9%no data
1.5%
Pontifax Venture Capital
288,873US$1.4m-68.5%1.41%
0.9%
Baldwin Wealth Partners, LLC
174,130US$816.7k3.26%0.06%
0.53%
Kenneth Hoberman
103,140US$483.7k0%no data
0.46%
Michael Carson
87,918US$412.3k866%no data
0.43%
Matthew Kaplan
83,760US$392.8k0%no data
0.41%
Geode Capital Management, LLC
79,716US$373.9k49.8%no data
0.35%
Millennium Management LLC
68,499US$321.3k-42.7%no data
0.3%
James Oliviero
57,828US$271.2k0%no data
0.29%
Iridian Asset Management LLC
55,380US$259.7k0%0.06%
0.26%
GSA Capital Partners LLP
50,129US$235.1k3.7%0.02%
0.26%
BlackRock, Inc.
49,554US$232.4k-40.6%no data
0.25%
J.M. Forbes & Co. LLP
48,401US$227.0k2.07%0.02%
0.22%
Marshall Wace LLP
42,814US$200.8k26.4%no data
0.14%
Two Sigma Investments, LP
26,785US$125.6k105%no data
0.14%
Susquehanna International Group, LLP, Asset Management Arm
26,463US$124.1k0%no data
0.12%
Qube Research & Technologies Ltd
22,433US$105.2k181%no data
0.1%
Charles Schwab Investment Management, Inc.
19,920US$93.4k0%no data
0.099%
Edmond de Rothschild Asset Management (France)
19,170US$89.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nuvectis Pharma, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Aydin HuseynovLadenburg Thalmann & Company
Jonathan AschoffRoth MKM